List of Biotech, Pharmaceutical & Life Sciences companies in Sweden - 146

2A Pharma is a clinical stage Swedish/Danish biopharmaceuticals company focused on discovering, developing and commercialising novel, cost effective prophylactic and therapeutic vaccines based on our patented vaccine platform. Our lead vaccine candidate, 2AP01, is a HPV (human papillomavirus) vaccine formulated without adjuvant. We believe 2AP01 will offer significant advantages over existing vaccines including broader protection against more HPV types and lower production cost. Our vaccine technology is based on adeno-associated virus-like particles (AAVLPs), that assemble viral capsids without containing viral genomes; hence they are replicative-defective and non-pathogenic. The viral capsid has repetitive immunogenic sites that can be modified to encompass antigenic epitopes for a protein of interest, generating an immune response where both the innate and the adaptive immune system are activated. In other words, 2A Pharma exploit the efficacy of the individuals’ own immune system to generate AAVLP-based vaccines that, without the addition of adjuvants, are able to develop highly effective antibodies with selected specificities and functions. The technology enables the production of highly efficient vaccines with significant competitive advantages

The commercially available Stockholm3- test, is a blood-test for early detection of prostate cancer. A3P Biomedical’s Stockholm3 test, combines protein markers, genetic markers and clinical data with an advanced algorithm in order to detect aggressive prostate cancer at early stage.

AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs in antibody-based medicine development. We aim to be a leading partner for the global biopharmaceutical industry focusing on a broad range of diseases including cancer, autoimmune disorders, and neurological conditions. We are committed to providing unparalleled expertise and innovative technologies that contribute to the advancement of novel antibody therapeutics. Technologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.

Abera Bioscience AB is a Swedish biotech company headquartered in Stockholm. We are dedicated to develop novel vaccines and vaccine development technologies to improve health worldwide. The Company's unique expertise in Biochemistry and Molecular Microbiology is based on many years of research and has generated a patented platform technology for the development of novel vaccines. Abera brings Outer Membrane Vesicle (OMV) technology to the next level by decorating their surface with a palette of antigens at a high density. To this end, Abera has adapted a natural system for bacterial protein secretion into the most efficient and versatile system for surface display of antigens known today. Abera's platforms allows the development of efficient multivalent, multi-stage vaccines for oral and nasal administration. It also enables faster and more cost-effective production. Abera's OMV-based vaccines can be manufactured within 14-30 days.

Acarix is a Swedish medical device company that innovates solutions for rapid Coronary Artery Disease (CAD) rule-out. The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing chest pain with suspected CAD and is designed to help reduce millions of unnecessary, invasive, costly diagnostic procedures. CADScor®System rapidly calculates a patient-specific CAD-score non-invasively with 96% confidence. Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

Acorai is developing a device for heart failure management through non-invasive cardiac and pulmonary pressure sensing, to help reduce hospitalizations and readmissions. Our product can monitor cardiac and pulmonary pressure sensing non-invasively through a machine-learning analysis of pressure dynamics in acoustics, vibratory, and waveform data. Our technology shows compelling precision, has a low-risk clinical and regulatory pathway, a low dependence on reimbursement, and a fast track to commercialization.

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

AcuCort has developed and commercializes Zeqmelit™, a new fast-dissolving oral film to put on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV) and for the treatment of patients with COVID-19 who need supplemental oxygen therapy. Zeqmelit™ is approved in Sweden, Denmark, and Norway; and AcuCort has signed its first commercial agreement. Altogether, this strengthens the company's assessment that the time to commercialization may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.se.

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that targets psoriasis, and B-cell driven autoimmune diseases respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. Affibody has ongoing commercial relationships with several companies such as AbClon, Alexion, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Affibody AB is a holding of Patricia Industries.

We, at Akira Science - a Stockholm based tech start-up-, use the latest manufacturing technologies to provide you with pliable scaffolds for soft tissue engineering. Our solutions results from the synergistic combination of degradable polymers synthesis expertise, mechanical simulation approach to develop suitable scaffold design to tailor the biological response.

Alba Health is on a mission to improve the health of next generations. Join our movement to fight the chronic disease epidemic from childhood.

At Alex Therapeutics we provide digital health solutions that enable pharmaceutical companies to better support their products, and their patients. Leveraging our proven modular technology platform allows partners to reduce time-to-market and enables frictionless deployment of safe, secure and effective digital health products. Over 100,000 patients have used our products globally, with our best-in-class user experience design ensuring better health engagement and outcomes.

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator´s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more than 60 billion unique antibody fragments. FIND® (Fragment Induced Diversity) is a molecular evolution technology for optimization of antibodies and other proteins. Immunotherapy of cancer: The immune system protects the body from attacks by pathogenic microorganisms (e.g. viruses and bacteria) and by cancer cells. Cancer cells usually evade the immune system, for example by producing immunosuppressive substances. Thus, although tumors often contain a large number of immune cells that should be able to attack the cancer cells, they are unable to do so due to the immunosuppression caused by the tumor. With immunotherapy, the ability of the immune system to fight cancer cells is improved in an effective manner, and the defense mechanisms used by the tumor are blocked or weakened. In addition, immune cells capable of destroying the cancer cells will survive in the body and thus protect it from metastases that may arise after treatment has ended. This "vaccination effect" is unique for immunotherapy.

AlzeCure Pharma is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops new, innovative, and effective drugs with a goal to combat Alzheimer's disease.

Alzinova AB is a Swedish clinical-stage biopharma company developing treatments for Alzheimer’s disease by specifically targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that has unique ability and precision to target the toxic amyloid-beta oligomers involved in the onset and progression of the disease. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further.

Amferia AB is a Swedish company that develops and markets new medical devices with emphasis on antibacterial products. The core focus of Amferia is to develop materials that can efficiently kill bacteria when used as medical devices, for example within wound care. Amferia is a spin-off from research performed at Chalmers University of Technology. The company was founded in 2018 and the founders of Amferia are Dr. Anand Kumar Rajasekharan, Professor Martin Andersson and Dr. Saba Atefyekta.

Amniotics was born out of the discovery of novel stem cells in full term amniotic fluid. Research on these cells has demonstrated a number of unique properties in them, highlighting their extraordinary suitability for medical applications. These properties, in combination with safe collection, ethical agreeability, tissues and high cell counts harbour the promise of the exciting journey we have started pushing medical boundaries. The science and research behind the discoveries on which the company is based has been carried out within the realms of the reputable Lund University in southern Sweden, one of its prime research centers BMC (Bio Medical Center) Research Center, and the university hospital in Lund. Therefore, Amniotics considers itself today to be uniquely positioned to translate stem cell technologies into novel and improved human therapeutics. Our ultimate vision is to contribute to the successful treatment of serious human diseases by providing the very best cells for various regenerative medical applications. The fact that our cells are of neonatal source (and safely retrieved from the amniotic fluid from C-sections), means that they have greater genome integrity. And also other positive attributes of the neonatal source of our cells makes them superior to traditional sources of stem cells that are currently in therapeutic use. As part of our commitment to providing the best cell therapeutics we are developing these for treatments with high unmet needs in collaboration with international renowned KOLs and partners. In a nutshell, we have designed and built a complete ecosystem for managing these cells in a safe, secure and controlled manner, which we are now expanding and scaling up. Our journey continues. We will push the boundaries of science within regenerative medicine to save and improve the lives of many. #regenerativemedicine, #stemcells #therapies

AMRA Medical is a health informatics company founded in 2010, originating from Linköping University in Sweden. With a team of over 30 employees and a global presence, AMRA specializes in AI-driven medical imaging and precision medicine, particularly in advanced MRI analytics for body composition assessment. The company has achieved regulatory clearances, including CE-Marked medical device status, and collaborates with major industry players like Pfizer Inc. AMRA offers next-generation phenotyping that utilizes AI to analyze whole-body MRI scans, providing precise fat and muscle biomarkers for personalized health insights. Their cloud-based platform ensures secure, quality-controlled results with a quick turnaround and is compatible with various MRI scanners. The company also develops imaging biomarkers and disease phenotypes through partnerships, aiming to create a global representative database. Under the leadership of CEO Eric Converse and co-founders Magnus Borga and Olof Dahlqvist Leinhard, AMRA focuses on equipping clinicians and researchers with actionable data to manage conditions such as obesity and metabolic disorders.

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022. You can find more information about AnaCardio at www.anacardio.com.

Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for the treatment of various cardiovascular diseases. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with cardiovascular diseases with vascular damages and inflammation. The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of Annexin A5. The production process is patented. ANXV has the ability to protect and repair the blood vessels as well as counteract the inflammation. ANXV is therefore expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major ones, such as heart attack. ANXV has the potential to become a First-In-Class drug (a product with new and unique mechanisms of action which is the first of its kind on the market) for several patient groups where there is considerable unmet demand for medical treatment.

Anocca understands the complexity of T-cell biology. We have established a unique technology platform that replicates functional human cellular immunobiology and unlocks the potential of T-cell immunotherapies and vaccine strategies that leverage T-cell immunity. Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity. Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.

Aptahem AB is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in patients diagnosed with a septic condition, among others. The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

Aiming to provide improved treatments for chronic respiratory diseases through new, innovative and patent protected substances, thereby reducing suffering and ameliorating quality of life for patients.

ArgusEye provides innovative sensor systems based on nanoplasmonic detection for real-time monitoring of biological systems and processes.

AroCell AB is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as Certified Adviser.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). About Orviglance (Mangoral) Orviglance* (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study. About Oncoral Oncoral is a novel oral irinotecan tablet in development. Irinotecan is a chemotherapy with established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Oncoral is initially developed for the treatment of gastric cancer, a cancer form with unmet needs and the opportunity for Orphan Drug status in the US and Europe. Following successful Phase 1 results, Phase 2 clinical development for Oncoral is in preparation. *Trademark is registered in Europe and several other markets and submitted for registration in the US.

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.

Basic Genomics AB is a technology-driven life science company that pioneers the characterization of nucleic acid molecules in single cells. We provide the missing layer in single-cell sequencing by enabling cost-efficient analysis of RNA isoforms in health and disease.

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.

BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products within the areas of gut, oral, immune and bone health. Our probiotic products with bacterial strains from the L. reuteri species are among the most scientifically well-documented probiotics. The class B share of BioGaia is quoted on the Mid Cap list of the Nordic Exchange Stockholm.

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

BioLamina is a Swedish biotechnology company with a global presence, offering cell culture matrices for primary cells. We offer an expansive portfolio of recombinant laminin proteins for a variety of applications, including the reliable expansion of pluripotent cell and differentiation and maintenance of specialized cell types. Our chemically defined and xeno-free laminin cell culture matrices allow you to imitate the natural cell-matrix interaction in vitro. Laminins are key components of the extracellular matrix. Through their interactions with specific receptors, laminins trigger the authentic cellular responses, pivotal for cell anchorage, survival, proliferation, migration, organization, and specialization, leading to improved cell functionality. BioLamina's laminins are the only original full length, human, recombinant laminins on the market. Our high technology products contribute to our customer's efficiency and scientific breakthroughs and enable them to start a new era in medical research. We are known and recognized for our premium products, competence, dedication, and service and position ourselves as being in the forefront of cell culturing. Our vision is to make BioLamina a leading brand within the field of cell culture and to help make cell therapy a reality. BioLamina is built on a scientific foundation with a legacy in matrix biology and solid experience in cell culture-based research. The company was started in 2009 and was co-founded by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason. Today the company has about 35 employees spanning from production, R&D, logistics, sales, and marketing. Our quality system complies with ISO 9001:2015 and both management and employees follow well-defined standard processes and agreements.

Bionamic was founded by researchers to address the frustrating challenge of implementing digitalization in biopharma R&D. Our software platform can serve as a single source of truth for all your antibody related discovery and development data and offers an easy way to navigate it. We have put an incredible amount of thought and effort into making sure the data can be represented in a way that makes sense and helps to solve real problems.

Biosergen’s antifungal drug candidate, BSG005, is the fruit of a groundbreaking effort over the last two decades by SINTEF (one of Europe’s largest independent research organizations) and the Norwegian University of Science and Technology (NTNU) to develop an improved version of Nystatin, a naturally occurring fungicidal chemical in the bacterial strain Streptomyces noursei. Work that to date has been published in more than 20 international peer reviewed scientific publications. BSG005 has been shown to have a broad spectrum of action. At similar dose levels, the drug demonstrates a three to four times in vivo potency advantage over the current standard of care for patients not responding to Azole and Echinocandin treatment. With this product profile BSG005 will fill the need for a product that offers fungicidal efficacy against a broad range of fungal strains. BSG005 appears to be without the gaps due to resistance development seen in other antifungals. Most importantly, in the GLP-tox tests and in recognized animal models it lacks the severe kidney toxicity seen with Amphotericin B formulations. BSG005 has also shown effect against resistant fungal strains and strains that have been difficult to treat with the drugs available on the market.

About Biotage Biotage is the Global Go-To Separations Company, supporting customers from drug discovery and development through to diagnostics and analytical testing with intelligent and sustainable workflow solutions. Our expertise and top-tier separation solutions play a key role in streamlining our customers' workflows and improving their outcomes. Headquartered in Sweden, Biotage operates globally with 700 employees, serving over 80 countries. Our company is listed on NASDAQ Stockholm (BIOT).

Biovica develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and predict patient outcomes. The company’s DiviTum™ TKa assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE-labeled and MPA-registered.

BONESUPPORT AB is a Scandinavian orthobiologics company based in Lund, Sweden, specializing in advanced bone graft solutions. Founded in 1999, the company develops and commercializes bioceramic products aimed at managing bone injuries. Its flagship product, CERAMENT®, is an injectable bioceramic material designed for bone void filling and infection management, featuring osteoconductive properties and drug-eluting capabilities for localized antibiotic delivery. The company operates globally, achieving net sales of SEK 899 million in 2024, with significant growth in both North America and Europe. BONESUPPORT focuses on direct commercialization in key markets and partnerships for global distribution. The leadership team includes experienced executives in business administration and orthobiologics, with a strong emphasis on clinical validation and innovative solutions for orthopedic surgeons, trauma centers, and hospitals.

Cantargia develops antibody based therapy against the target IL1RAP. The lead candidate CAN04 is for treatment of solid tumors and hematoligacal cancers, entering phase I/IIa clinical development.

Carbiotix is an award-winning biotechnology company pioneering the onsite upcycling of plant-based side-streams. Carbiotix mission is to improve the health of people by increasing the consumption of prebiotics and other active ingredients from upcycled side-streams. Carbiotix offers one core service today called NutraCycle, an on-site upcycling and fortification service allowing food & beverage, ingredient, and feed producers to turn plant-based products into healthier, more profitable, and sustainable products.

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.

We are a Nordic biotechnology company with a broad pipeline of innovative groundbreaking drug candidates and derma cosmetic products. Our projects have great potential for treating patients with serious diseases such as cancer and diabetes complications and improving the quality of life for people in need of cosmetic products in hair growth. The strategy is to create value by developing and commercializing derma cosmetic products in partnership with significant commercial players and early handing over "first-in-class" drug candidates to larger pharmaceutical companies. Coegin Pharma has three established portfolio companies through Follicum AB, Reccura Therapeutics AS and Avexxin Oncology AS.

Medical Device Coatings and Drug development to improve outcome of kidney transplantation.

Cyxone AB (publ) is a clinical stage biotech company that develops new innovative therapies for the treatment of rheumatoid arthritis and multiple sclerosis. The company's goal is to improve the quality of life for patients with autoimmune and autoinflammatory diseases.

Diamyd Medical is a Swedish diabetes company developing precision medicine therapies for Type 1 Diabetes. The therapeutic diabetes vaccine Diamyd , an antigen-specific immunotherapy for the preservation of endogenous insulin production, is being evaluated in the ongoing Phase III trial DIAGNODE-3. The company is establishing a vaccine manufacturing facility in Umeå for the manufacture of recombinant GAD65, the active ingredient in the diabetes vaccine. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB. The Diamyd Medical share is traded on Nasdaq First North Growth Market, ticker DMYD B.

Diaprost is a private pharmaceutical research and development company based in Lund, Sweden. The company's principal asset is hu5A10, a novel Theranostic Antibody licensed for development in the treatment and diagnosis of prostate cancer. Diaprost has also announced promising new studies for patients with metastatic prostate cancer, and has entered into license agreements with other companies for the development of its products.

Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications.

Dizlin Pharmaceuticals AB is a privately held Swedish research-based pharmaceutical development company with focus on diseases of the central nervous system in general and on developing improved treatment for advanced stages of Parkinson's disease in particular. The company conducts research in collaboration with researchers at the University of Gothenburg and Linköping University in Sweden. The company has developed a new patented method for treatment of advanced stages of Parkinson's disease. Dizlin Pharmaceuticals has two products in late phase development stage. The first - Infudopa IntraV™ – is administered intravenously to minimize risks associated with surgery on patients with Parkinson's disease. The second – Infudopa SubC™ – is administered as a continuous subcutaneous infusion by means of a portable pump (similar to insulin infusion for diabetes).

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We've been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in 120 countries and listed on Nasdaq Stockholm. Visit elekta.com to learn more.

Elicera Therapeutics is a clinical stage cell and gene therapy company focusing on immunooncology. The company develops CAR T-cells against both solid and liquid tumors based on its proprietary technology platform, iTANK, for a parallell activation of an innate immune response against cancer. Elicera also develops next generation oncolytic viruses with three combined mode-of-actions, applicable for treatment of most cancers.

Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome – system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer noninvasively. Elypta is advancing a broad clinical program across different cancers with the first indication expected to be early detection of recurrence in renal cell carcinoma. Several years of research in Nielsen lab at Chalmers University of Technology in Gothenburg, Sweden led to the founding of Elypta in May 2017 by Francesco Gatto and Jens Nielsen.

Our ambition is to play a key role in tackling climate change, by enabling green chemistry for every industry. We do this by creating the most general and efficient technology platform for chemical production that the world has ever seen. That’s a big claim, but we can stand behind it. By bio-upgrading the chemical industry with our cell-free biomanufacturing platform, we can produce the products that modern society relies on in a truly sustainable way. The technology platform utilises nature’s catalysts, enzymes, by combining the power of biology with the efficiency of the chemical industry in a best-of-both-worlds solution. EnginZyme is recognised as a Technology Pioneer by World Economic Forum and backed by Sofinnova Partners, Industrifonden, SEB Greentech VC, Bunge Ventures, Almi Invest GreenTech Fund, and Navigare Ventures.

Epigenica is a life sciences technology company at the forefront of innovations in epigenetic research. The company's EpiFinder platform enables researchers to perform comprehensive epigenetic studies at unprecedented speed, scalability, and affordability. Epigenica is building a portfolio of products based on the EpiFinder platform to offer comprehensive high-throughput profiling at different depths of detail with an array of possible starting materials. The platform is powered by the company's patented and proprietary high-throughput, multiplex, quantitative ChIP-seq technology (hmqChIP), the first commercial kit of its kind. With the advantages of the EpiFinder platform, Epigenica is helping researchers advance biomedical research, drug discovery and development, precision medicine, diagnostics, and therapeutics for aging and longevity.

EQL Pharma AB (publ) is a pharmaceuticals company based out of Skåne County, Sweden.

Eurocine Vaccines is a highly merited vaccine development company operating at the heart of the bio-scientific cluster of Karolinska Institutet, Sweden, thus attracted several internationally recognized vaccine specialists to its board. Through our portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with an extensive future leverage. These candidates are later licensed to partners for commercialization. We call it – Bridging the Gap between Innovation and Market. Whilst we continuously are in search of new candidates to our portfolio, these following projects are our currently given our prime attention. Chlamydia – A protein based candidate currently scaled up into a industrially manufactured process which ensure high quality supply for the forthcoming studies, beginning with the Toxicological study planned for autumn 2022 followed by Phase 1 study planned to be conducted in 2023. HSV2 – A very promising candidate that either can be developed as a prophylactic or therapeutic vaccine, based on either protein or mRNA technology.

Fluicell is transforming how we treat disease with one-of-a-kind tissue solutions for regenerative medicine and drug screening. With the groundbreaking Nexocyte platform, based on twenty years of disruptive and patent-protected R&D, we are creating new ways to target serious diseases using precision-engineered biological tissues. Our transplantable tissues have the potential to help patients living with uncurable tissue damage related to cardiac, pulmonary, metabolic, kidney and other diseases. Fluicell's first ambitious goal is to develop transplantable tissues to cure type 1 diabetes, impacting the lives of millions of patients. Nexocyte-generated tissues also enable our world-leading partners to advance their drug-screening capabilities for the development of game-changing medicines.

Gedea Biotech develops pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can be very disturbing and include an often profuse thin, white, “fishy” smelling vaginal discharge. Standard treatment consists of antimicrobials, but recurrence rate is 15–30 % within 3 months. pHyph will treat the infection and prevent recurrence without the use of antmicrobials. Antimicrobial resistance is one of the World Health Organisation’s top ten threats to global health and research into novel non-antimicrobial based treatments is timely.

Genovis offers a unique range of rapid and easy to use enzymatic tools primarily for the biopharmaceutical industry. Available worldwide, these SmartEnzymes™ are supplied in innovative formats for the development, production and quality control of biological drugs such as monoclonal antibodies, ADCs, biosimilars and bispecifics. The Genovis SmartEnzymes are widely used for the digestion, de-glycosylation and conjugation of the target molecule and are an ideal companion to popular analytical techniques like LC-MS. Within the portfolio there are enzymes specific for: IgG digestion - FabRICATOR™, FabALACTICA™, GingisKHAN™, FabULOUS™ & FabRICATOR Z™ General proteolysis - GingisREX™ De-glycosylation and conjugation of IgGs - GlycINATOR™, IgGZERO™ and GlyCLICK™ O-glycan analysis - OglyZOR™, OpeRATOR™, GlycOCATCH™ and SialEXO™

Drug candidates with a unique mechanism of action, aiming to reduce inflammation and pain. Vipoglanstat to enter phase II for endometriosis.

Gradientech is a Swedish in vitro diagnostics company that supports the modern microbiology lab with cutting-edge solutions to facilitate the workflow with time-critical samples. Our product, QuickMIC®, is an ultra-rapid system for antibiotic susceptibility testing (AST) of positive blood culture samples from sepsis patients. QuickMIC® is a scalable system with each instrument analysing one sample against a tailored gram-negative antibiotic panel. MIC values are reported in as short as 2 hours, making it more rapid than any other diagnostic system for phenotypic AST. Gradientech's technology combines microfluidics with live imaging to analyse bacterial responses on a linear antibiotic concentration gradient. The revolutionary technology delivers MIC values with unprecedented precision in record time.

Guard Therapeutics is developing innovative therapies focusing on kidney diseases. The company's lead clinical asset, RMC-035, is in phase 2b development for the prevention and treatment of kidney injuries in patients undergoing open heart surgery. The company also has preclinical candidate drugs intended for the treatment of chronic kidney disease, targeting specific disease segments such as FSGS, IgAN, Alport Syndrome and DKD. Listed on Nasdaq First North Growth Market.

Gyros Protein Technologies provides enabling peptide synthesis and bioanalytical solutions helping scientists increase biomolecule performance and productivity in pre-clinical/clinical development and bioprocess applications. The automat

Hansa Biopharma, is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative and life altering treatments for patients with rare immunological conditions. Hansa scientists are working on developing immunomodulatory treatments for organ transplants, rare IgG-mediated autoimmune conditions, and gene therapy, as well as exploring the potential application of the technology platform in oncology.

Iconovo is a leading Swedish CDMO company, offering innovative and effective inhalation platforms to the international pharmaceutical industry. We have several types of patented dry powder inhalers that can create significant commercial opportunities for the development of both new pharmaceuticals and generic medicine. Our strength is our inhouse capabilities with full control over both device development and formulation, meaning less risk and faster time to market.

The company is developing immunotherapies that use microorganisms to deliver stable therapeutic proteins

ImmunoIVD focuses on molecular assays for neonatal screening. The SPOT-it™ kit is CE marked and has been developed to facilitate population-scale screening to detect newborns with SCID, XLA and/or SMA. The company is built on a strong foundation with more than 30 years experience of successfully running a biotech company, and world renowned researchers within the field of clinical immunology and immunogenetics. Early detection increases the chances for children born with SCID, XLA and SMA to live life to its fullest. We believe all children should be given that chance.

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”. The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer on the market, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

Infant Bacterial Therapeutics AB (IBT) is a pharmaceutical company dedicated to developing drugs that prevent diseases in premature infants and combat the spread of antibiotic-resistant illnesses. IBT’s primary focus is on IBP-9414, a drug candidate containing Lactobacillus reuteri, a bacterial strain found in breast milk. The aim of IBP-9414 is to reduce the occurrence of necrotizing enterocolitis (NEC) and improve sustained feeding tolerance (SFT) in premature infants. Currently, IBP-9414 is undergoing a pivotal Phase III study for registration. IBT also has other drug candidates, including IBP-1016 for treating gastroschisis, IBP-1118 for preventing retinopathy of prematurity (ROP), and IBP-1122 for eliminating vancomycin-resistant enterococci (VRE) causing hospital acquired infections. By developing these drugs, IBT addresses medical needs that lack available treatments.

We focus on development, modification and production of custom antibodies, as well as their antigens; typically synthetic peptides and recombinant proteins. With more than two decades of experience of delivering products and services in the field of molecular biology, we have a complete toolbox of taking a project from idea to finished antibody – and beyond.

Insufficient iron levels lead to fatigue, focus issues, headaches, heart palpitations, learning disabilities, and depression. Low iron not only impacts women and girls but also the elderly, children, vegetarians, vegans, and those with chronic illnesses. This, mainly female, problem can affect performance levels and cause productivity and income gaps between men and women from an early age in life. Ironic has developed a portfolio of patented non-animal heme iron compounds with absoption rates comparable to the iron in meat. We produce them sustainably through precision fermentation. Our product is tasteless and stable, so it can be taken as pills or mixed in foods. We are also working with food companies to add our bioavailable iron directly into food products.

The Karolinska Institute is a research-led medical university in Solna within the Stockholm urban area of Sweden. It covers areas such as biochemistry, genetics, pharmacology, pathology, anatomy, physiology and medical microbiology, among others.The Institute is developing aDNA vaccine against COVID-19with electroporation delivery in partnership with Cobra Biologics as part of the OPENCORONA Project.

Kemwell is a contract biologics development and CMO company providing services to global biopharmaceutical organizations. Kemwell facilities, located in Bangalore, India, are designed and developed with technological support from a leading German pharma company. Kemwell provides customers with cost-effective access to state-of-the-art technology for all mammalian cell culture based products' development and manufacturing. 15,000 sq. m. Kemwell facility consists of a cGMP drug substance manufacturing area with over 4500L bioreactor capacity, sterile fill and finish areas for cGMP drug product manufacturing and process development laboratories to support production of protein therapeutics from mammalian-cell culture – monoclonal antibodies, bi-specific antibodies, fusion proteins, etc. Kemwell is capable of supporting novel, bio-better and biosimilar programs' preclinical development, clinical development, cGMP clinical manufacturing and cGMP commercial manufacturing. Kemwell, having established in 1980, had long term associations with pharma majors such as Bayer, GlaxoSmithKline, Merck KGaA, Novartis, Pfizer and others for small molecule contract mfg. and R&D. In 2016, Kemwell divested its small-molecule division to focus on biologics, leveraging its vast and rich experience. Kemwell is now a 100% biologics CDMO.

Klaria AB is a pharmaceutical company developing innovative pharmaceuticals for migraine, cancer-related pain and opioid overdoses.

Life Genomics is a private genetic laboratory which was founded in 2014 through the spin-off from TATAA Biocenter AB, to develop offers of genetic tests to the healthcare industry and the public. Life Genomics have two tests on the market: Non-invasive prenatal tests (NIPT) and PCR-test for Covid-19. Further tests are under development.

Lipidor AB is a Stockholm-based formulation research company. Its lipid based technology, AKVANO® represents an innovative dosage form consisting of water-free, sprayable liquid formulations in which selected lipids and the active ingredient are dissolved in a volatile solvent. The novel formulation technology offers unique product opportunities across dermatology, wound and skin care markets. The Company develops topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.

Lipum aims for better quality of life for the millions suffering from chronic inflammatory diseases, including children. Distressed by pain, disability, and comorbidities many have to leave a normal working life in advance. We intend to increase their quality of life and decrease the considerable health care and societal costs.

LOKON PHARMA is a Swedish biotech company in the forefront of developing immunostimulatory gene therapy for cancer-based on oncolytic viruses. Innovative gene engineering, solid expertise in cancer biology and immunology, as well as a genuine curiosity in life science expand Lokon’s pipeline towards groundbreaking new therapeutics for patients with high unmet medical need.

We specialise in medical technology for digital pathology and aim to improve tissue diagnostics with our patented technology. With technology based on up-converted nanoparticles (UCNP), high-quality images are generated with increased contrast and decreased irrelevant background noise. These images shorten turnaround time and provide higher-quality data for analysis. Lumito is a spin-off from a research team at Lund University's Division of Atomic Physics and Laser Centre and is planning to launch its product SCIZYS for research laboratories initially.

We are a Swedish company developing immunoassays for life science research. Our goal is to aid research by providing the scientific community with innovative tools, in particular for ELISpot, FluoroSpot, and ELISA. To that end, we develop and produce a wide range of monoclonal antibodies, kits, peptide pools, and instruments for in vitro applications. We started off in Stockholm in 1986, and our headquarters still lies in Nacka Strand, just east of the inner city. We do everything here, from research and production to finance, IT, quality control, marketing, distribution, and sales. In addition, we have a sales office in Cincinnati, Ohio, and collaborate with great distributors around the globe. The quality of our products really comes down to our entire organization; the balance between individual action and care for the collective. Because for us, quality isn't just a word. It's a mindset, a mantra, and a lens we hold to all our initiatives, whatever the size. As part of the scientific community, we want to do our share to help science progress. So we hope you see us as peers – feel free to strike up any sort of conversation with us.

Medivir is a drug discovery and development company focusing on transformative cancer drugs. Their research and development are based on their extensive knowledge of protease inhibition and nucleoside/nucleotide science. The company is headquartered in Stockholm, Sweden.

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.

Mentice, founded in 1999 and based in Sweden, is a leader in medical simulation solutions focused on image-guided interventional therapies (IGIT). The company has transitioned from providing endovascular simulators to offering comprehensive IGIT performance solutions aimed at enhancing clinical outcomes through advanced training and procedural optimization. Mentice is publicly traded on Nasdaq First North Growth Market under the ticker MNTC. The company provides a range of software and hardware simulation solutions designed to improve clinical performance in minimally invasive procedures. Key products include the VIST® series of haptic-enabled simulators for vascular procedures and MIST® systems for basic endovascular training. Mentice also offers portable platforms and integrated performance solutions that optimize workflow and assess clinician competency. The use of haptic feedback technology allows for realistic training in complex interventions. Mentice collaborates with global medical device companies and healthcare institutions, including notable partnerships with Terumo and Abbott. The company aims for significant annual sales growth and has expanded its geographic reach, including establishing an office in Chicago. Mentice is committed to addressing the demand for safer and more efficient minimally invasive procedures.

Moberg Pharma is a specialist pharmaceutical company focused on commercializing innovative products for the treatment of common diseases. The company's goal is to make MOB-015 the world's leading treatment for nail fungus and to build a specialty pharmaceutical company with its own sales.

Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s near-term focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.

Moleculent is a biotechnology research company that focuses on mapping and analyzing cell-cell interactions and communication directly within their tissue environment. The company's platform allows for the detection of healthy cell function and the analysis of functional proteins, including receptors and ligands.

Nanexa AB is a drug delivery company that focuses on the development of PharmaShell®, a new and pioneering drug delivery system that is considered to have great potential in a number of substance types and indication areas. Within the framework of PharmaShell®, Nanexa develops its own projects and has collaborative agreements with several pharmaceutical companies, including AstraZeneca.

Navinci is a Swedish biotech company that specializes in developing innovative solutions for the study of protein interactions. With a focus and a strong legacy in the development of in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth. Our Naveni Proximity Ligation Technology is at the forefront of innovation within the field of spatial proteomics and allows for the detection and quantification of protein interactions and post-translational modifications in a manner that is both sensitive and specific. It provides researchers with a valuable tool for their studies and helps deepen the understanding of the interplay between proteins in their native environment. Our latest focus is on target-specific kits within immuno-oncology, which detect interactions such as PD1/PD-L1. These kits are designed to help researchers easily visualize the interactions between immune checkpoint proteins in immune and cancer cells and elucidate the role that interactions, rather than individual proteins, play in the development of cancer. By providing researchers with reliable and innovative tools for visualizing and interpreting protein interplay, Navinci pushes forward the understanding of cell biology and brings precision to spatial proteomics.

NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden.  Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy.

NextCell Pharma is an innovative Biotech growing out of the need for Advanced Therapy Medicinal Products for Autoimmune Disease and Transplantation. Cellaviva, the first Swedish family saving stem cell bank, with its expertise in umbilical cord stem cells and Diamyd Medical with its interests and investments within autoimmune diseases made a natural partnership for creating NextCell Pharma. Clinical trials testing NextCell Pharma's first product, ProTrans,has started in Novermber 2018. #nextcellpharma #cellaviva

Oblique Therapeutics AB (publ.) is a Swedish biotech company developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. The company uses Abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome.

Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways. Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base. For more information visit www.olink.com

Omnio AB is a biopharmaceutical company dedicated to revolutionizing the treatment of diabetic foot ulcers (DFUs) through the development of recombinant plasminogen therapeutics.

Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on Nasdaq Stockholm with the ticker ONCO. For more information, visit: www.oncopeptides.com

Oncorena is aiming to save human lives by transforming a natural substance into a breakthrough therapy treatment for advanced kidney cancer. We have completed all preclinical studies and are moving into early-stage clinical development. The objective is to confirm the powerful anti-tumor activity of our drug candidate - based on the natural substance orellanine - in advanced kidney cancer patients. Oncorena AB is headquartered in Lund, Sweden.

OncoZenge is developing BupiZenge™, a lozenge based on the safe and effective non-opioid, long acting pain reliever bupivacaine. BupiZenge’s primary indication is oral mucositis and it has the potential to help millions of people with their oral pain caused by radiotherapy and chemotherapy.

OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. Website: www.ossdsign.com Newsroom: https://news.cision.com/ossdsign-ab (Always consult Instructions for Use which accompany the products for complete indications, contraindications, warnings and precautions.)

We are a clinical-stage medtech company developing an innovative implant for ileostomy patients. Our TIES implant aims to allow people with a stoma to take back control of their lives. With the TIES implant there is no need to continually wear a colostomy bag. Patients can feel safe and secure - no bag, no leaks, no smell, no noise.

Back in the 1970’s a microbiologist named Milt Allison was studying interactions between feedstuffs and microbes at the National Animal Disease Laboratory in Ames, Iowa. Dr. Allison noticed that some sheep, after feeding off a high-oxalate containing plant (Halogeton glomeratus), were mysteriously dying from kidney failure. After further research, he realized that surviving sheep actually had developed a tolerance to oxalate as their microbiomes gradually adapted to a diet of this plant. Dr. Allison’s studies showed that the better tolerance was caused by an increased number of oxalate-degrading bacteria in the sheep gut. In further studies, Dr. Allison and his team of graduate students, isolated this oxalate-degrading bacterium. They found that the bacterium metabolizes oxalate converting it to formate, so they named it Oxalobacter formigenes. They also found that it occurs in the gastrointestinal tracts of many animals, including humans. OxThera AB was founded in 2005 to explore the therapeutic potential that originated from this observation. Turning a naturally occurring bacteria into a healthcare product may sound easy, but in reality, it is not. To commercialize Oxabact®, we needed to develop a large-scale manufacturing process and a suitable delivery mechanism to transport uniform quantities of live bacteria to the site of action. The bacterium viability demands strict anaerobe conditions making biomanufacturing complex. We have developed a lyophilized formulation encapsulated in a special enteric coating that protects the bacteria from the stomach acid. The capsule remains intact while passing through the stomach, then releases cells at the target site.

Pelago Bioscience AB is founded to accelerate the use and value of the CETSA® technology in Drug Discovery and diagnostics. We know that the need for Target Engagement studies is large and increasing and there is no single technology with the same opportunities to fill this need as CETSA®. We will: - Make more relevant data available to our customers at an earlier stage of the Drug Discovery process - Enable filtering of compounds based on physiologically relevant data to facilitate better decisions in Drug Discovery programs - Provide our customers with CETSA® based Target Engagement data in vitro and in vivo - Improve translation from laboratory to patient by using a single technology - CETSA® - Facilitate development of novel medicine in clinical trials using CETSA® - Develop diagnostic kits, companion diagnostics and tools for monitoring Target Engagement during patient treatment using CETSA® Pelago Bioscience AB will by these accomplishments add value to Drug Discovery programs allowing for faster and better development of new and improved drugs. By developing the CETSA® technology for general clinical use as a diagnostic and treatment monitoring tool we aspire to improve the lives and health of patients.

We are on a mission to build a comprehensive product portfolio dedicated to women's intimate health. Our approach is rooted in the ability to diagnose, treat, and prevent concerns, blending science with aesthetically appealing and beautiful products. We firmly believe women's intimate care should be grounded in scientific exploration. This commitment to research ensures that our products are effective and backed by a robust foundation of research and knowledge. Join us on a movement to redefine women's intimate health.

Perimed AB is a Swedish company, founded in 1981 and headquartered just outside Stockholm. Perimed develops, manufactures and markets state-of-the-art diagnostic equipment to assess microcirculation and peripheral perfusion as well as Peripheral Arterial Disease. We offer solutions for clinical use as well as for research. We have more than 40 years of experience and unique competence in fiber optics, laser and camera optics, as well as tissue optics making Perimed a leader in measuring and assessing microcirculation and peripheral macro circulation. Perimed is a global company with subsidiaries in USA, China, France, Italy and Germany. Our customers in the other countries are supported either directly from our Swedish headquarters or by our certified local distributors listed on our contacts pages.

PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company's drug candidate, PN6047, effectively reduces neuropathic pain in animal models and the findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported. Furthermore, PN6047 exhibited none of the adverse events typically associated with the conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or signs of abuse potential. This validates the unique preclinical profile of PN6047, which shows that it acts extremely selectively on the delta opioid receptor distinguishing it fundamentally from conventional opioids that target the mu opioid receptor. PN6047 is Phase II ready!

Phase Holographic Imaging is a company that specializes in live cell imaging and analysis systems, enabling label-free kinetic live cell studies during physiologically optimal conditions. They also provide time-lapse cytometers for long-term imaging and analysis of cell cultures using a patented method that allows living cells to be studied without the use of labels or dyes.

Single cell spatial proteomics. Molecular Pixelation uses DNA-conjugated antibodies and DNA encoded pixels to identify and spatially locate cell surface proteins.

Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process, and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden's Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally.

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market.

Qlife is a Danish medical technology company that develops an innovative medical technology platform with the long-term goal of giving people access to safe and validated blood biomarker data at home. The platform called Egoo.health consists of a small diagnostic device with individual capsules containing each a specific biomarker test that can be measured by a single drop of blood from the fingertip.

Q-linea AB is a Swedish medical technology company based in Uppsala, founded in 2007. The company focuses on developing innovative solutions for infection diagnostics, aiming to enhance the diagnosis and treatment of infectious diseases, particularly sepsis. Q-linea's mission is to provide rapid and accurate diagnostic tools that benefit patients and healthcare providers. The company specializes in in-vitro diagnostic systems, with its key product being ASTar, an antibiotic susceptibility testing system for positive blood cultures. This system aids healthcare providers in diagnosing and treating infections by delivering critical information on antibiotic resistance, thereby helping to reduce antibiotic misuse. Q-linea employs a targeted commercial strategy in key European markets, including the UK, Italy, and Benelux, and has established partnerships to expand its reach. Under the leadership of CEO Stuart Gander, Q-linea has made significant strides in its growth and product development. In 2023, the company raised approximately SEK 263 million through a rights issue to support its strategic initiatives and achieved IVDR certification for its diagnostic products.

Qlucore makes it easier to analyze the huge amounts of complex data that are generated by innovations in the fields of genetics and proteomics. It is done by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. The easy to use tools empowers researchers, technicians and physicians to easily interpret and explore their datasets.

Developing state-of-the-art AAV vectors for gene therapy

Rarity Bioscience provides ultra-sensitive multiplex assays for mutation detection in blood and other liquid biopsies for research, pharma and labs. The superRCA technology is based on padlock probes and rolling circle amplification, enabling extreme sensitivity and specificity, and utilize well established high throughput flow cytometry for the read-out. The company was founded in 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology, and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.

ADVANCING CANCER TREATMENT RaySearch is advancing cancer treatment through pioneering software. Software has unlimited potential, and we believe it is now the driving force for innovation in oncology. Medical science never stands still, and neither does RaySearch. We work in close cooperation with leading cancer centers to bring scientific advancements faster to the clinical world. Today, our solutions support thousands of clinics worldwide in the fight against cancer. And this is just the beginning.

Recipharm is a leading global CDMO dedicated to meeting your evolving needs through operational excellence, scientific know-how, and customer connectivity. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering. Our worldwide reach paired with in-depth, localised market knowledge allows us to anticipate our customers’ needs and strengthen the support we provide to forge a healthier, more expansive and more fruitful future together. With a workforce of 5 200 people, we are focused on supporting pharmaceutical companies with our full-service offering, taking products from early development through to commercial production. Since our inception in 1995, we have supported our customers throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again to ensure their products are delivered with certainty.

Redoxis is a preclinical boutique CRO specializing on inflammation and autoimmune conditions. We provide in vivo, ex vivo and in vitro preclinical efficacy and MoA studies. We have a fully equipped lab with capacity to perform a wide range of cell based assays as well as immunology assays to provide you everything form MoA studies to PK and in vivo efficacy studies.

SAGA Diagnostics is a personalised cancer medicine and disease monitoring company focused on molecular genetic analyses of circulating tumor DNA and tissue biopsies.

SARomics Biostructures provides a broad range of structural biology and drug discovery services that include: X-ray crystallography services: Protein cloning, expression, characterization, and crystallization, FastLane™ Standard and FastLane™ Premium off-the-shelf structures, gene-to-structure services. Protein NMR spectroscopy: Peptide NMR & protein NMR assignment, peptide NMR & protein NMR structure determination, protein-ligand & protein-protein complex structure determination, fragment screening using 1D or 2D NMR spectroscopy, epitope mapping and dissociation constant (Kd) determinations for compounds, biosimilars higher order structure (HOS) verification & comparability analysis, formulation characterization and optimization, expression and purification of 2H, 15N, and 13C-labelled protein in E.coli for NMR spectroscopy studies and structure determination. Structure-based lead discovery services: Fragment screening and fragment-based drug design, computational chemistry, in silico drug discovery services. Our integrated drug discovery platform relies on our unique and proprietary weak affinity chromatography screening technology (WAC™). Antibody & antibody-antigen 3D structure determination, higher order structure (HOS) comparability analysis of biosimilars. Why choose SARomics Biostructures The commitments of our highly experienced and competent team of crystallographers, modelers, and molecular biologists include: Swift replies to all contact requests. After the initial project discussion, we provide realistic project timelines. We guarantee high quality services. We have a high degree of customer satisfaction. Our robust technology platform is built around a wide variety of experimental methods required in modern structural biology. We use a unique and verified proprietary method for compound screening. We benefit from an excellent location in Medicon Village in Lund and proximity to one of the world's best synchrotrons, MAX IV.

We are a research-based specialty biopharma company determined to give people all over the world a longer and better life. We are developing the first vaccine for protection against diarrhoea caused by ETEC in both travellers and endemic populations. We distribute a wide range of specialty biopharma products with focus on vaccines and immunoglobulins.

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com

Senzime is a leading global medical device company, developing precision-based patient monitoring solutions that drive a global paradigm shift in perioperative patient safety. Our cutting-edge solutions TetraGraph and ExSpiron 2Xi are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory functions during and after surgery. With our dedicated team and strong partnerships, we are on a global mission to safeguard every patient's journey, from anesthesia to recovery. Established in 1999, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). #senzime #tetragraph #patientsafety #tofmonitoring #anesthesia

Introducing next-generation RNase inhibitors - ideal for single-cell and in situ RNA-sequencing SEQURNA's RNase inhibitor makes RNA work and sequencing pipelines more accessible, affordable, and sustainable. Unlike competitors’ recombinant RNase inhibitors, the SEQURNA inhibitor is thermostable and can be shipped and stored at room temperature without affecting performance. These features do not only simplify shipping and storage logistics, eliminate batch effects, and reduce costs for the user – but also enable new and simplified workflows as well as novel laboratory protocols including heat cycles. Propel your biotech business or research, and choose a more environmentally sustainable option for RNase inhibition in your RNA-seq workflows, by becoming an early user of SEQURNA’s RNase inhibitor. Our R&D team is keen to assist and advice in the transition. Find out more at www.sequrna.com or email us at info@sequrna.com

We develop technologies for ultrasensitive analysis of complex DNA sources. Compared to other technologies for ultrasensitive sequencing, our solutions are both simple to use and specifically adapted for analysis of difficult to analyze DNA such as circulating tumor DNA, a biomarker specific for cancer.

SINGLE TECHNOLOGIES develops a new type of single molecule sensitive 3D sequencing system.

SmartCella, founded in 2014, is an innovative biotechnology and medtech company based in Stockholm, Sweden. SmartCella’s vision is to combine first-in-class delivery platforms with cutting-edge cell and gene therapies to unleash the full potential of targeted therapies. The company has three main business units, Smartwise, SmartCella Solutions and Procella. Smartwise is developing and manufacturing a first-in-class endovascular delivery device, the Extroducer, that enables direct tissue/organ infusions through the vessel wall directly into to hard-to-reach organs and tumors. There is a significant unmet need in the field of targeted delivery of different types of therapies for regeneration of tissue and for treatment of cancer tumors. Smartwise received regulatory approval from the US FDA for the Extroducer in June 2022 and is now actively out-licensing the technology to global companies with therapies that benefit from direct delivery. SmartCella Solutions create novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs or microenvironments. A pipeline of projects within regeneration and tolerization, focusing on oncology, is in pre-clinical development. Procella has advanced capabilities within stem cell therapy development and inhouse cGMP manufacturing of cell based therapies, with a proven platform to take stem cell projects from discovery phase to clinical development. A globally licensed cardiac stem cell therapy is entering clinical stages (in collaboration with AstraZeneca) and there is a growing pipeline of projects in different stages of development, with dopamine producing cells for Parkinson´s Disease and our own iMSCs most advanced.

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology, immunology, and specialty indications. Today, we employ approximately 1,800 people across Europe, North America, the Middle East and Asia. In 2023, our revenue amounted to SEK 22.1 billion. The Sobi share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

Spiber Technologies uses recombinant technology for producing advanced biomaterials. Our primary goal is to develop and commercialize state-of-the-art patented technologies based on the recombinant spider silk protein Spiber™ and the solubility tag SolvNT™ Spiber™-based products can be used as 3D scaffold for culturing stem cells and creating future Regenerative Medicine applications. SolvNT™ can increase solubility for recombinant production of peptides and proteins. The company was founded in 2008. The technologies are based on the successful research on spider silk conducted at the Swedish University of Agricultural Sciences (SLU), the Royal Institute of Technology (KTH) and Karolinska Institutet (KI). The company is privately owned and located in Stockholm, Sweden.

For customers working in the life sciences and pharma industry, Svar offers a unique combination of scientific expertise, high-quality assay products, strong services, and proprietary technology platforms that provide a flexible, effective, and seamless experience for customers through different development needs in a way that no other single business can. At Svar, we are dedicated to our customers' development journey. We harness a deep understanding and long-standing experience in immunological areas such as complement system activation and immunogenicity. We utilize this in our expert cell engineering, assay development, and contract research services capabilities. Our specialist knowledge allows us to help you tackle complex problems, safely and efficiently moving your candidates through the drug development phases and to the patient—also when standard solutions fall short.

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, we employ approximately 1,800 people across Europe, North America, the Middle East and Asia. In 2022, our revenue amounted to SEK 18.8 billion.

Cell metabolism and monitoring made easy - label-free and continuous measurements of biological activity. Multi-channel assay that measures the specific metabolic phenotype for cells and pathogens in real-time with exceptional precision. Return to phenotype - The calScreener™ cell-based assay provides a phenotype response measurement with unprecedented sensitivity and versatility. We enable: Smarter drug development - Bridge the gap between in-vitro and in-vivo testing Rapid and accurate diagnostic - Customize treatments for infections due to multi-resistant bacteria Want to see what others cannot? All living cells produce heat during metabolism. We measure this heat at unsurpassed precision. No heat equals no metabolism. The only absolute measurement of death. We make it possible to see what was previously impossible. Applications are limited only by the imagination of the scientist. Bacteria. Cells. Organoids. Worms. Ants. Feces. If it fits in the tube we can measure it. Symcel is a biotechnology company located in Stockholm and was founded by Dr. Dan Hallen and Prof. Ingemar Wadsö in 2004, leading authorities in the field of biocalorimetry.

SynAct Pharma is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral melanocortin receptor agonists for the treatment of inflammatory diseases. For more information, visit https://synactpharma.com/en/

Syntach AB is innovation-driven company based in Lund, Sweden. The Company develops an entirely new class of minimally invasive cardiac support devices and other products aimed and improving the lives of millions of patients living with advanced stage heart failure.

At TATAA Biocenter, we offer PCR bioanalytical services to address the challenges in nucleic acid therapy drug development. Our mission as a CRO is to provide assay development, validation, and high-throughput analyses with high sensitivity for regulated and non-regulated bioanalysis, clinical biomarkers, and manufacturing quality assessments to accelerate your time-to-market. As your extended workbench of specialists and dedicated partner, we prioritize quality, innovation, and building strong client relationships. We are a GLP-accredited, GCLP-compliant, and ISO/IEC 17025-certified laboratory. Our purpose-built facility for nucleic acid analyses enhances sensitivity and minimizes contamination risks. With state-of-the-art instrumentation and an IT structure ensuring the highest data integrity and sample management, our collaborative and highly skilled scientists deliver advanced competence and precise execution.

Thioredoxin Systems AB is a biotechnology company developing a novel antibiotic regimen against pathogenic bacteria. EbsArgent is a patented combination of ebselen and silver, capable of functioning as an antiseptic, antibacterial in food production, and as a medicinal product. With its versatility and ability to act on a wide range of multi-drug resistant bacteria, it is among the most promising antibiotic regimen under development today.

Toleranzia develops protein-based antigen-specific immune tolerogens to cure patients with autoimmune diseases. The drugs have the potential to become the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. The company has a lead project in myasthenia gravis as well as a second project in ANCA vasculitis. Toleranzia is listed on the Nasdaq First North Growth Market and backed by strongly committed renowned specialist investors.

Umecrine Cognition is a pharmaceutical company that is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company's drug candidate, golexanolone, has a unique product profile that addresses important clinical needs and is also the only drug of its class under development. Umecrine Cognition is headquartered in Solna, Sweden and is focused on addressing important unmet medical needs in the field of central nervous system disorders.

VERIGRAFT generates personalized tissue-engineered transplants for use in regenerative medicine. The company's unique technology platform turns donated allogeneic ("foreign") tissue into an autologous-like ("personalized") tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogenic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes. VERIGRAFT's development pipeline comprises products in the areas of vascular regeneration as well as peripheral nerve repair.

Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

At Viedoc, we design engaging software that modernizes clinical research so that necessary treatments can reach the people who need them faster. We believe in life and science, in people, and in our collective power to change the world and build a healthier future. That unmatched driving force is what pushes us to innovate, accelerate and improve every aspect of modern clinical studies. Since 2003, Viedoc has united scientists and clinical trial professionals in a shared mission of pushing life-changing research forward. Our solution has been used to power thousands of studies, by collecting data from over a million patients and allowing it to flow smoothly across sites and countries. We take great pride in helping bridge the gap between patient and researcher – and, in the best of cases, between research and breakthrough.

The Vitrolife Group is a world-leading global provider of medical devices and genetic testing testing solutions. Dedicated to the reproductive-health market since 1994, we have grown by focusing on product development, groundbreaking research, consistent quality control and acquisitions of innovative companies in the industry. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services primarily for IVF clinics. Together we are now the Vitrolife Group, a global leader in reproductive health focused on supporting our customers and patients worldwide to improve treatment outcomes – always with sustainability in mind. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire reproductive-health journey, providing consistent performance and guaranteed quality. Currently, we are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 125 countries, through our own presence in more than 25 countries and a vast network of distributors for the rest of the world. We are on a mission to be the leading valued solution provider in reproductive health and to support customers with successful treatment outcomes.

WntResearch is developing a completely new type of cancer drug that inhibits the ability of tumour cells to spread in the body and form metastases. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumour cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 per cent of all cancerrelated deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer. WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com.

Xinnate is a young biopharmaceutical company built on groundbreaking scientific research about innate defence and healing mechanisms – evolutionary biological systems with the purpose of keeping us healthy. One of these innate defence peptides has shown to be an effective ”natural” and unique way of preventing infection as well as reducing excessive inflammation. Xinnate specializes in the development of proprietary peptide-based drugs for prevention and treatment of inflammatory diseases and infections within the areas skin and wounds, surgical materials and and biomaterials. The company was founded in 2019 and is based on 15 years of world class research from Lund University. The first area to be addressed by Xinnate is advanced wound care, and the first product is a hydrogel, the BioC wound gel, aimed for treatment of burn wounds.

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.

Single-cell and Bulk RNA-sequencing services.

Xspray Pharma (Nasdaq Stockholm: XSPRAY) aims to improve patients' quality of life by developing and producing pharmaceuticals, based on world leading technology and deep industry expertise. Xspray Pharma uses its innovative, patented, and scalable technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The company has several product candidates in clinical development and a wide pipeline of potential candidates. The proven HyNap technology allows the company to gain entry before the secondary patents expire and can thereby benefit patients rapidly. Xspray Pharma's first product XS0004 dasatinib is pending FDA approval and has received orphan drug status in the US. Xspray Pharma's management team has extensive experience from the pharmaceutical industry. The company is based in Stockholm and shares are traded on Nasdaq Stockholm. www.xspraypharma.com

Ziccum is developing new dry-powder versions of the world’s most urgently-needed vaccines. These new, gently air-dried formulations can be transported easily and cost-effectively, with no costly cold storage or refrigeration required.